Newfound Research LLC Sells 64 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Newfound Research LLC trimmed its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 28.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 162 shares of the medical instruments supplier’s stock after selling 64 shares during the period. Newfound Research LLC’s holdings in West Pharmaceutical Services were worth $69,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of WST. Maverick Capital Ltd. bought a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $31,000. Bbva USA bought a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $37,000. CX Institutional boosted its holdings in shares of West Pharmaceutical Services by 128.3% during the 2nd quarter. CX Institutional now owns 105 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 59 shares in the last quarter. West Branch Capital LLC bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth $38,000. Finally, FFT Wealth Management LLC bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth $46,000. Hedge funds and other institutional investors own 92.65% of the company’s stock.

In other news, VP Quintin J. Lai sold 9,672 shares of the firm’s stock in a transaction on Friday, September 10th. The stock was sold at an average price of $460.76, for a total transaction of $4,456,470.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.66% of the company’s stock.

A number of equities analysts recently issued reports on WST shares. KeyCorp increased their target price on West Pharmaceutical Services from $350.00 to $475.00 and gave the stock an “overweight” rating in a report on Friday, July 30th. Zacks Investment Research cut West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $438.00 target price on the stock. in a report on Friday, November 12th.

NYSE WST traded up $3.03 on Thursday, reaching $433.72. The company had a trading volume of 280,588 shares, compared to its average volume of 395,772. The stock has a market capitalization of $32.13 billion, a P/E ratio of 53.81, a P/E/G ratio of 1.79 and a beta of 0.98. The company’s fifty day moving average is $426.04 and its 200 day moving average is $400.37. West Pharmaceutical Services, Inc. has a 52-week low of $253.85 and a 52-week high of $475.35. The company has a quick ratio of 2.23, a current ratio of 2.86 and a debt-to-equity ratio of 0.10.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 28th. The medical instruments supplier reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.26. The business had revenue of $706.50 million during the quarter, compared to analyst estimates of $687.09 million. West Pharmaceutical Services had a return on equity of 30.35% and a net margin of 22.85%. West Pharmaceutical Services’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 EPS. On average, research analysts expect that West Pharmaceutical Services, Inc. will post 8.43 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 17th. Stockholders of record on Wednesday, November 10th were given a dividend of $0.18 per share. The ex-dividend date of this dividend was Tuesday, November 9th. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.17. This represents a $0.72 annualized dividend and a dividend yield of 0.17%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 8.93%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.

Recommended Story: The primary rules of Elliott Wave theory

Want to see what other hedge funds are holding WST? Visit to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with's FREE daily email newsletter.